Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children
Summary
Third Opinion Trial Synopsis:
This study looks at how well a medicine called carfilzomib works with other drugs called cyclophosphamide and etoposide to treat children with cancer that has come back or didn't go away after treatment. Carfilzomib is only approved for adult cancer patients, but they want to see if it's safe and effective for kids. They will decide how much of each drug to use and see if there are any bad side effects.
This study looks at how well a medicine called carfilzomib works with other drugs called cyclophosphamide and etoposide to treat children with cancer that has come back or didn't go away after treatment. Carfilzomib is only approved for adult cancer patients, but they want to see if it's safe and effective for kids. They will decide how much of each drug to use and see if there are any bad side effects.
*Third Opinion AI Generated Synopsis
Trial Summary
This study evaluates the use of carfilzomib in combination with cyclophosphamide and etoposide for children with relapsed/refractory solid tumors or leukemia. The medications cyclophosphamide and etoposide are standard drugs often used together for the treatment of cancer in children with solid tumors or leukemia. Carfilzomib is FDA (Food and Drug Administration) approved in the United States for adults with multiple myeloma (a type of cancer). However, this drug is not approved to treat children with relapsed/refractory solid tumors or leukemia. With this research, we plan to determine the DLTs and MTD of Carfilzomib given in combination with cyclophosphamide and etoposide in pediatric patients with relapsed/refractory leukemias and solid tumors.
This study evaluates the use of carfilzomib in combination with cyclophosphamide and etoposide for children with relapsed/refractory solid tumors or leukemia. The medications cyclophosphamide and etoposide are standard drugs often used together for the treatment of cancer in children with solid tumors or leukemia. Carfilzomib is FDA (Food and Drug Administration) approved in the United States for adults with multiple myeloma (a type of cancer). However, this drug is not approved to treat children with relapsed/refractory solid tumors or leukemia. With this research, we plan to determine the DLTs and MTD of Carfilzomib given in combination with cyclophosphamide and etoposide in pediatric patients with relapsed/refractory leukemias and solid tumors.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: